DTU researchers develop an AI platform for designing customized proteins for target cancer immunotherapy.
Alisa Davidson
Post: July 25, 2025 10:25 AM Update: July 25, 2025 9:52 am
Edit and fact confirmation: July 25, 2025 10:25 am
simply
Researchers at the University of Technology have developed an AI -based platform that quickly designs customized proteins to guide immune cells that target cancer by anticipating clinical trials within five years.
Researchers at the University of Technology have introduced an AI -based platform designed to accelerate the development of customized proteins that support the immune system response to cancer. This system enables the production of special proteins within a few weeks, which promotes immune T cells in identifying and attacking cancer cells.
This platform is an engineering “mini -linder” protein that integrates three AI models and attaches to T cells and provides molecular guide mechanisms that target cancer such as black species. This approach is applied to develop proteins that are extensively occurring and to develop proteins adjusted to both patient-specific cancer markers, suggesting potential applications in personalized oncology.
To configure these molecular tools, the researchers first used a creation model known as RFDIFION to investigate the structure of cancer-related proteins called NY-ESO-1, which is generally present in tumor cells. The second AI model produced an amino acid sequence predicted to be folded into an accurate structure that can be binded to this target. The third model has improved the results and filtered tens of thousands of generated sequences with 44 candidates for laboratory evaluation. One of these designs showed effective performance.
The platform also includes a virtual safety screening process that anticipates and excludes protein designs that can interact with healthy tissues, improving safety before physical tests occur. Workflow integrates ALPHAFOLD2, a protein forecasting tool that has been developed by Google Deepmind, and traditionally compresses the development cycle of many years.
AI-Enhanced Cell Therapy is expected to enter human exams within 5 years
One of the team’s researchers, Timothy Patrick Jenkins, is expected to take about five years for the newly developed method to proceed to the initial clinical trial stage related to human participants. When prepared for application, the treatment protocol is generally expected to coincide with existing cancer therapy using Gene-manipulated T cells called CAR-T cells, which is approved to deal with treatment conditions such as lymphoma and leukemia.
The treatment process begins with blood lottery performed in a hospital environment similar to a standard blood test. The immune cells are then separated from the collected samples and contain AI production mini -linders in the laboratory environment. These changed immune cells are designed to be reintroduced into the patient’s body and operated with high precision, and positioned cancer cells with targeted accuracy.
The latest research is part of the development trend of computational biology. Earlier this year, the team of the Timothy Patrick Jenkins also developed an engineering protein to improve the effect of snake -bit antibeoms by applying AI.
disclaimer
The trust project guidelines are not intended and should not be interpreted as advice in law, tax, investment, finance or other forms. If you have any doubt, it is important to invest in what you can lose and seek independent financial advice. For more information, please refer to the Terms and Conditions and the Help and Support Pages provided by the publisher or advertiser. Metaversepost is doing its best to accurately and unbiased reports, but market conditions can be changed without notice.
About the author
Alisa, a dedicated reporter for MPOST, specializes in the vast areas of Cryptocurrency, Zero-ehnowedge Proofs, Investments and Web3. She provides a comprehensive coverage that captures a new trend and a keen eye on technology, providing and involving readers in a digital financial environment that constantly evolves.
More
Alisa Davidson
Alisa, a dedicated reporter for MPOST, specializes in the vast areas of Cryptocurrency, Zero-ehnowedge Proofs, Investments and Web3. She provides a comprehensive coverage that captures a new trend and a keen eye on technology, providing and involving readers in a digital financial environment that constantly evolves.
More